Cantor Fitzgerald Reaffirms Overweight Rating for LifeMD (NASDAQ:LFMD)

Cantor Fitzgerald reaffirmed their overweight rating on shares of LifeMD (NASDAQ:LFMD) in a research note released on Friday, Benzinga reports. Cantor Fitzgerald currently has a $15.00 price objective on the stock.

Several other equities analysts have also weighed in on the company. B. Riley started coverage on LifeMD in a report on Friday, August 23rd. They set a buy rating and a $11.00 price objective for the company. KeyCorp cut their price target on LifeMD from $12.00 to $10.00 and set an overweight rating for the company in a research note on Thursday, July 11th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of Buy and a consensus target price of $12.00.

LifeMD Trading Down 7.0 %

Shares of LifeMD stock opened at $4.91 on Friday. The firm has a market cap of $205.03 million, a PE ratio of -6.64 and a beta of 1.19. LifeMD has a 1 year low of $4.05 and a 1 year high of $12.88. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.87 and a quick ratio of 0.83. The stock has a fifty day moving average price of $5.70 and a 200-day moving average price of $7.82.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $50.66 million for the quarter, compared to analyst estimates of $48.47 million. During the same quarter last year, the company posted ($0.23) earnings per share. Equities research analysts anticipate that LifeMD will post -0.49 EPS for the current year.

Institutional Trading of LifeMD

Hedge funds and other institutional investors have recently made changes to their positions in the stock. G2 Investment Partners Management LLC boosted its position in shares of LifeMD by 23.9% in the fourth quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company’s stock valued at $5,704,000 after acquiring an additional 132,850 shares during the period. Vanguard Group Inc. boosted its holdings in LifeMD by 12.5% in the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after purchasing an additional 128,701 shares during the period. Bank of New York Mellon Corp boosted its holdings in LifeMD by 63.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock valued at $1,609,000 after purchasing an additional 91,183 shares during the period. Acadian Asset Management LLC grew its position in shares of LifeMD by 261.8% during the 1st quarter. Acadian Asset Management LLC now owns 116,655 shares of the company’s stock valued at $1,198,000 after purchasing an additional 84,413 shares in the last quarter. Finally, Cantor Fitzgerald L. P. bought a new position in shares of LifeMD in the fourth quarter worth $653,000. 35.52% of the stock is currently owned by institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.